3725 related articles for article (PubMed ID: 26001391)
21. LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways.
Chung SW; Bae SM; Lee M; Al-Hilal TA; Lee CK; Kim JK; Kim IS; Kim SY; Byun Y
Biomaterials; 2015 Jan; 37():271-8. PubMed ID: 25453957
[TBL] [Abstract][Full Text] [Related]
22. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.
Homsi J; Daud AI
Cancer Control; 2007 Jul; 14(3):285-94. PubMed ID: 17615535
[TBL] [Abstract][Full Text] [Related]
23. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats.
Fernandez M; Mejias M; Garcia-Pras E; Mendez R; Garcia-Pagan JC; Bosch J
Hepatology; 2007 Oct; 46(4):1208-17. PubMed ID: 17654489
[TBL] [Abstract][Full Text] [Related]
24. Beyond bevacizumab: antiangiogenic agents.
Rogosin S; Sandler AB
Clin Lung Cancer; 2012 Sep; 13(5):326-33. PubMed ID: 22297207
[TBL] [Abstract][Full Text] [Related]
25. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
26. Combination antiangiogenic therapy and radiation in head and neck cancers.
Hsu HW; Wall NR; Hsueh CT; Kim S; Ferris RL; Chen CS; Mirshahidi S
Oral Oncol; 2014 Jan; 50(1):19-26. PubMed ID: 24269532
[TBL] [Abstract][Full Text] [Related]
27. VEGF-A/VEGFR-2 and FGF-2/FGFR-1 but not PDGF-BB/PDGFR-β play important roles in promoting immature and inflammatory intraplaque angiogenesis.
Mao Y; Liu X; Song Y; Zhai C; Zhang L
PLoS One; 2018; 13(8):e0201395. PubMed ID: 30125282
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer.
Huang Y; Carbone DP
Biochim Biophys Acta; 2015 Apr; 1855(2):193-201. PubMed ID: 25598052
[TBL] [Abstract][Full Text] [Related]
29. Anti-Angiogenics: Current Situation and Future Perspectives.
Zirlik K; Duyster J
Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
[TBL] [Abstract][Full Text] [Related]
30. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.
Choi HJ; Armaiz Pena GN; Pradeep S; Cho MS; Coleman RL; Sood AK
Cancer Metastasis Rev; 2015 Mar; 34(1):19-40. PubMed ID: 25544368
[TBL] [Abstract][Full Text] [Related]
31. VEGF signaling in cancer treatment.
Sia D; Alsinet C; Newell P; Villanueva A
Curr Pharm Des; 2014; 20(17):2834-42. PubMed ID: 23944367
[TBL] [Abstract][Full Text] [Related]
32. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
33. Sprouting strategies and dead ends in anti-angiogenic targeting of NETs.
Carrasco P; Zuazo-Gaztelu I; Casanovas O
J Mol Endocrinol; 2017 Jul; 59(1):R77-R91. PubMed ID: 28469004
[TBL] [Abstract][Full Text] [Related]
34. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.
Ferrara N
Semin Oncol; 2002 Dec; 29(6 Suppl 16):10-4. PubMed ID: 12516033
[TBL] [Abstract][Full Text] [Related]
35. [Molecular tumor board-renal cell carcinoma].
Grünwald V; Doehn C; Goebell PJ
Urologe A; 2019 Jul; 58(7):768-773. PubMed ID: 31175376
[TBL] [Abstract][Full Text] [Related]
36. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
37. Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development.
Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Uemura M; Fukui H
Oncol Rep; 2005 May; 13(5):853-7. PubMed ID: 15809749
[TBL] [Abstract][Full Text] [Related]
38. Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S; Rich JN
Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
[TBL] [Abstract][Full Text] [Related]
39. Angiogenesis inhibitors: a rational strategy for radiosensitization in the treatment of non-small-cell lung cancer?
Raben D; Helfrich B
Clin Lung Cancer; 2004 Jul; 6(1):48-57. PubMed ID: 15310417
[TBL] [Abstract][Full Text] [Related]
40. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.
Taeger J; Moser C; Hellerbrand C; Mycielska ME; Glockzin G; Schlitt HJ; Geissler EK; Stoeltzing O; Lang SA
Mol Cancer Ther; 2011 Nov; 10(11):2157-67. PubMed ID: 21885862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]